- Report
- March 2024
- 180 Pages
Global
From €3217EUR$3,374USD£2,742GBP
€3574EUR$3,749USD£3,046GBP
- Report
- November 2023
- 87 Pages
Global
From €5672EUR$5,950USD£4,835GBP
- Report
- June 2024
- 92 Pages
Global
From €5339EUR$5,600USD£4,551GBP
- Report
- March 2024
- 200 Pages
Global
From €3956EUR$4,150USD£3,372GBP
- Report
- March 2018
- 220 Pages
Global
From €1783EUR$1,870USD£1,520GBP
€2097EUR$2,200USD£1,788GBP
Diastat is a brand of central nervous system (CNS) drugs used to treat seizures. It is a form of diazepam, a benzodiazepine, and is administered rectally. Diastat is used to treat acute repetitive seizures, also known as status epilepticus, in patients aged 6 months and older. It is also used to treat cluster seizures in patients aged 5 years and older. Diastat is available in a variety of forms, including a gel, a liquid, and a rectal suppository.
The Diastat market is a subset of the larger CNS drugs market. CNS drugs are used to treat a variety of neurological conditions, including epilepsy, Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The Diastat market is highly competitive, with a number of companies offering similar products.
Some of the companies in the Diastat market include Mylan, Teva Pharmaceuticals, Sun Pharmaceuticals, and Actavis. Show Less Read more